Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

Amplia Therapeutics announced today that its lead FAK inhibitor AMP945 has been granted the International Nonproprietary Name (INN) of ‘narmafotinib’.

Commonly referred to as a generic name, an INN is used to identify pharmaceutical substances and active pharmaceutical ingredients.

The process of assigning a name to a drug compound involves an extensive review procedure prior to approval. This review considers similarity to existing drug names, ease of pronunciation across multiple languages, language review for accidental meaning, and finally a period for parties to voice objections regarding the proposed name.

Amplia’s CEO and Managing Director, Dr Chris Burns, commented:

“Approval of the name narmafotinib is an important step in the commercial development of the drug, signaling to potential partners and collaborators our commitment to the long-term development of this exciting agent.”

Click link below to read the full ASX Release.

International Nonproprietary Name announced for AMP945

International Nonproprietary Name announced for AMP945